


# 2025 SUMMER SYMPOSIUM & RECEPTION

MAY 31, 2025 | METROPOLITAN CLUB AT WILLIS TOWER, CHICAGO, IL



# 20TH ANNIVERSARY



Committed to discovering, developing, and providing novel therapies that significantly improve the lives of patients



www.TAVALISSEhcp.com



www.GAVRETO-hcp.com



www.REZLIDHIAhcp.com

Please see Full Prescribing Information, including Boxed Warning at <u>www.REZLIDHIAhcp.com</u>. **2025 Corporate Partners** 



# 2025 Annual Oncology Supporter

# Johnson&Johnson

**2025 Annual Exhibitors** 





# indications, patients, possibilities

Patient portrayal.



Scan to learn more at KISQALI-HCP.COM



Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080



### CONTENTS

Ever	nt Sponsors	page 1
Abo	ut CAHON	page 3
Upc	oming CAHON Events	page 5
Prog	gram	page 8
Abo	ut Our Speakers	page 9
CAH	ON Young Investigator Awards	page 10



### **ABOUT CAHON**

Founded by Chinese American Hematologists and Oncologists in 2005, the primary missions of CAHON are to foster communications amongst Chinese American medical professionals for the delivery of high-quality health care to patients with neoplastic and hematological diseases, and to promote medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a bridge among its members and between Chinese and American Hematology-Oncology communities for medical and educational exchange.



### THE STORY BEHIND THE LOGO

CAHON'S logo was designed by Drs. Weijing Sun, Ke Liu, and Jeffrey Ye, under the supervision of the CAHON Board. The design has the following elements and takes the following considerations:

- The overall shape represents the globe.
- The blue, white, red and yellow represent the colors of two nations' flags. China and the US.
- The yellow and red stripes above the blue represent bridges. One of CAHON's key missions is to serve as a bridge between Chinese American Hematology-Oncology communities for medical and educational exchange.
- The white space is in the shape of a heart. The hearts of our members continue to drive our mission to provide high quality patient care to everyone.

#### **CAHON MEMBERSHIP**

By joining CAHON you will have access to:

- A growing network of Chinese American professionals working in your field
- A private WeChat group where you can submit clinical questions to respected colleagues who are knowledgeable in specific areas of hematology and oncology
- Reduced or waived registration fees for all CAHON events and meetings along with priority hotel reservations
- Members-only section of the CAHON website featuring the member directory; and
- Travel award opportunities

### **MEMBERSHIP CATEGORIES**

Regular/Active Membership Associate Membership Allied Membership

Visit cahon.org/membership for more information on membership.



# See the 5-year data in patients who took Verzenio (abemaciclib)



Scan the QR code to learn more



# A Lilly Medicine





PP-AL-US-4619 11/2024  $\odot$ Lilly USA, LLC 2024. All rights reserved. Verzenio $^{\circ}$  is a registered trademark owned or licensed by Eli Lilly and company, its subsidiaries or affiliates.

### 12<sup>th</sup> Annual New York Oncology Forum (NYOF) & CAHON 20th Anniversary Celebration

October 4-5, 2025 Sheraton LaGuardia East Flushing, NY

The CAHON annual New York Oncology Forum (NYOF) is a one-and-a-half-day educational program that includes presentations on new developments and updates from the latest ASH, ASCO and SITC meetings including novel agents for Hematology and Oncology. This annual event draws more than 100 clinicians, researchers, medical students, clinical fellows as well as laboratory and health care related scientists working in hematology and oncology. The members only CAHON 20<sup>th</sup> anniversary celebration will take place in the evening on Saturday, October 4<sup>th</sup>.

### Winter Symposium and Reception

Saturday, December 6, 2025 Westgate Lakes Resort Orlando, FL

Held in conjunction with American Society of Hematology's (ASH) annual meeting, the Winter Symposium will offer expert perspectives and practical insights on current advancements in a variety of cancer treatments, as well as foster collaboration and provide a forum for interaction and collaboration between hematologists and oncologists.





# Learn about a metastatic pancreatic cancer regimen.





©2025 Ipsen Biopharmaceuticals, Inc. All rights reserved. NON-US-004053 04/25





# DISCOVER A **NEW APPROVAL** FOR CABOMETYX



CABOMETYXhcp.com

### SATURDAY, MAY 31, 2025, 5:30 – 10:00 PM CDT

5:30 – 7:00 pm	Doors and Registration Open, Social Gathering, Visit Exhibit Booths
7:00 – 7:30 pm	CAHON Presentations
	<b>Opening Remarks and Board of Directors Update</b> Jing-Zhou Hou, MD, PhD – CAHON Board Chair, University of Pittsburgh Medical Center
	CAHON Presidential Address and CAHON Updates Liang Deng, MD, PhD – CAHON President, Memorial Sloan Kettering Cancer Center
	<b>Updates on CAHON Journals</b> Delong Liu, MD, PhD – <i>Editor-in-Chief, Journal of Hematology &amp; Oncology, NY Medical College</i>
7:30 – 8:30 pm	Panel Discussions
7:30 – 8:00	<ul> <li>Life After Fellowship: Strategies for Success in Academia, Industry, and Community Practice</li> <li>Moderators: Cynthia Ma, MD, PhD – Washington University Charles Jiang, MD, MPH – UT Southwestern</li> <li>Panelists: Peter Q. Jiang, MD PhD – John B. Amos Cancer CenterTianhong Li, MD, PhD - UC Davis Comprehensive Cancer Center</li> <li>Minggui Pan, MD, PhD – Stanford University</li> <li>Yucai Wang, MD, PhD – Mayo Clinic</li> <li>Jianda Yuan, MD, PhD – Merck</li> <li>Wanqing Iris Zhi, MD, PhD – NYU Langone, Perlmutter Cancer Center</li> </ul>
8:00 – 8:30	<ul> <li>From Bench to Clinic: Innovation and Entrepreneurship in Hematology and Oncology</li> <li>Moderators: Liang Deng, MD, PhD – CAHON President, Memorial Sloan Kettering Cancer Center Jing- Zhou Hou, MD, PhD – CAHON Board Chair, University of Pittsburgh</li> <li>Panelists: Zhihong Chen, MD – Curon Biopharmaceutical Ke Liu, MD, PhD – Marengo Therapeutics Wenru Song, MD, PhD – Kira Pharma Yang Liu, PhD – OncoC4, Inc.</li> <li>Pan Zheng, MD, PhD – OncoC4, Inc. Sen Zhuang, MD, PhD – Johnson &amp; Johnson</li> </ul>
8:30 - 8:50 pm	Young Investigator Awards Ceremony Hong Zheng, MD, PhD,   Wanqing Iris Zhi, MD, PhD,   Minggui Pan, MD, PhD, Huichun Zhan, MD, MS   Elizabeth Budde, MD, PhD CAHON 2024-2026 Academic Committee
8:50 – 9:00 pm	<b>Closing Remarks</b> Jing-Zhou Hou, MD, PhD – <i>CAHON Board Chair, University of Pittsburgh Medical Center</i>
9:00 – 10:00 pm	Social Gathering

\*Food and drinks will be provided throughout the symposium.

# **Meeting Organizers**

Jing-Zhou Hou, MD, PhD – CAHON Board Chair, University of Pittsburgh Medical Center Liang Deng, MD, PhD - CAHON President, Memorial Sloan Kettering Cancer Center Cynthia Ma, MD, PhD – Washington University Minggui Pan, MD, PhD – Stanford University Yucai Wang, MD, PhD - Mayo Clinic Tian Zhang, MD, MHS – UT Southwestern Wanqing Iris Zhi, MD, PhD - NYU Langone, Perlmutter Cancer Center

# **YIA Recipients**



#### Guo Cheng, MD

I was born in Kunming, a scenery city in the southwest of China. My journey into medicine began at Zhejiang University School of Medicine where I fell in love with medicine and science. After medical school, I pursued PhD and postdoc

training at the University of California, Los Angeles. I had the privilege to work on a challenging project where we identified Tumor Endothelial Marker 7 as the cell surface receptor of PEDF (pigment epithelium-derived factor), the most potent antiangiogenic protein in the human body. This discovery revealed a novel anti-angiogenic pathway that is specific to tumor blood vessels. We went on to develop first-in-class drugs to target this pathway for cancer treatment. Currently, a joint effort from academia and industry is preparing the top candidates for clinical trials. To realize my dream as a physician, I joined Greater Baltimore Medical Center for residency training in Internal Medicine. Here, I strive to build my clinical skills and find my passion for a career in the field of hematology and oncology.



#### Jiasen He, MD

Dr. Jiasen He earned his medical degree from Shanghai Jiao Tong University School of Medicine and completed his pediatric residency at the University of Florida, Pensacola. He then pursued a pediatric hematology-oncology fellowship at

MD Anderson Cancer Center, where he served as co-chief fellow. Currently, he is completing a pediatric neuro-oncology fellowship.

Dr. He's research focuses on immunotherapy and targeted therapies for rare pediatric cancers, particularly pediatric brain tumors. He is an active member of the esteemed laboratory led by Drs. Juan Fueyo and Candelaria Gomez-Manzano, where he has been investigating oncolytic viruses for chemotherapyresistant pediatric cancers, including diffuse midline glioma (DMG). His work has been presented at major conferences such as ASCO, SNO, and SITC and has earned him the prestigious Caroline Ross Endowment Fellowship in Brain Cancer Research.

Notably, his innovative proposal combining virotherapy with CAR T-cell therapy for DMG secured a fellowship grant from the ChadTough Foundation. Dr. He has received widespread recognition for his research, with numerous poster and oral presentations at ASH, SNO, and the SNO Pediatric Neuro-Oncology Conference. His publications span prestigious journals, including Neuro-Oncology, Leukemia, Translational Pediatrics, Cancer Research Communications, IJMS, JPHO, Immuno, and Cancers.

Looking ahead, Dr. He plans to continue his clinical practice and research at MD Anderson, focusing on immunotherapy for pediatric brain tumors and associated toxicities.



#### Yuqing Wang, MD, PhD

Dr. Yuqing Wang graduated from Tongji University in 2018 with a Bachelor of Clinical Medicine, earning highest honors and the National Scholarship. She went to complete her Ph.D. in Molecular Physiology and Biophysics at Baylor

College of Medicine, where she developed a novel probioticbased drug delivery system for immune modulation in autoimmune disease. This work was published in the Proceedings of the National Academy of Sciences and recognized (PNAS) and received national recognitions. She also earned a Certificate of Added Qualification in Clinical and Translational Research while at Baylor.

Dr. Wang is currently an Internal Medicine resident at Montefiore Medical Center in New York. In addition to her clinical responsibilities, she is actively involved in research with a focus on autoimmune diseases, cancer immunology, and immunotherapy. Her recent work explores the use of large language models to simplify cancer-related terminology and improve patient education, particularly for those with limited health literacy. This project was selected for presentation at the 2025 annual meetings of both the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Inspired by these experiences, now she aspires to become an oncologist who bridges clinical care and research to advance equity and innovation in cancer treatment.

Dr. Wang's work has been recognized with several honors, including the Chinese Government Award for Outstanding Self-Financed Students Abroad, the Women of Excellence Award from Baylor College of Medicine, the Teaching Star Award from Montefiore, and the Emerging leader alumni award from Tongji University recently. Her diverse academic and clinical background reflects her deep commitment to advancing both research and patient care.

# **YIA Recipients**



#### Lawrence Wu, MD, MS

Dr. Wu is a 2nd year hematology/medical oncology fellow at Columbia University Irving Medical Center. His current clinical and research focus is on improving care and treatments for patients with gastric cancer. He obtained a

Bachelor's and Master's degree at University of Pennsylvania and also conducted laboratory based research on improving targeted therapies in melanoma in the lab of Dr. Meenhard Herlyn. He attended medical school at UT Southwestern and graduated in 2020. Afterwards, he went to Johns Hopkins Hospital for internal medical residency.



#### Jiazhang Xing, MD

Dr. Xing completed her undergraduate studies in Biology at Tsinghua University, followed by medical school at the Peking Union Medical College, where she graduated in 2023. She is currently a PGY-1 resident at Sinai Hospital of

Baltimore, with a strong aspiration to become an oncologist. During medical school, she participated in research projects on gastrointestinal neuroendocrine tumors and immunotherapy. Her current research focuses on addressing the socioeconomic needs of cancer patients.



#### Maggie Yuxi Zhou, MD

Maggie Yuxi Zhou is a chief and third-year hematology and oncology fellow at Stanford University with an academic focus in sarcoma. She graduated from Yale University with a BA and double majored in economics and molecular,

cellular, and developmental biology. She subsequently received her MD from Stanford University School of Medicine, where she stayed for internal medicine residency and fellowship.

Her research interests center around the development of novel therapeutics, understanding pathophysiology of rare sarcoma subtypes, and evaluating the utility of circulating tumor DNA for disease response and monitoring. She has over 20 peerreviewed publications, including in Clinical Cancer Research, Nature Cell, and The Journal of Biological Chemistry. She received the 2024 Catalyst Award from the Sarcoma Alliance for Research through Collaboration to develop in partnership with her co-awardee, Dr. Everett Moding, a protocol to assess the efficacy of CSF1R inhibition in leiomyosarcoma. Her work in ctDNA assessment in soft tissue sarcoma was recognized with Best Poster Awards at the annual Connective Tissue Oncology Society meeting in 2022 and 2024.

She is an active member of the Sarcoma Clinical Trial Working Group in the Hoosier Cancer Research Network, in addition to the American Society of Clinical Oncology, American Society of Hematology, Connective Tissue Oncology Society, and American Association for Clinical Research.



© Johnson & Johnson and its affiliates 2025 05/25 cp-514193v1

Johnson&Johnson

NOW APPROVED IN TWO NEW 1L INDICATIONS

# TEVINBRA® (tislelizumab-jsgr) Injection, for intravenous use 10 mg/mL



# BE THE FIRST TO SEE THE DATA

Scan here for 1L results that can't be ignored.

1L, first line.

TEVIMBRA and BeiGene are registered trademarks owned by BeiGene, Ltd. or its affiliates. © BeiGene, Ltd. 2024 All Rights Reserved. 1024-TEV-PRC-081 01/25

# LOOK CLOSER TO SEE WHAT THALASSEMIA IS HIDING

It may not always be apparent, but serious risk of morbidities can exist in some patients regardless of transfusion history.<sup>1,2</sup>



LEARN MORE AT www.rethinkthalassemia.com/hcp



References:

lusallam KM, Cappellini MD, Daar S, Taher AT. Morbidity-free survival and hemoglobin level in non-transfu t-halassemia: a 10-year cohort study. Ann Hematol.2022;101(1):203-204. 2. Musallam KM, Taher AT, Cap reated anemia in nontransfusion-dependent β-thalassemia: time to sound the alarm. European Hematolog ients featured have been compensated for their participation. os Pharmaceuticals. Inc. © 2024 All right reserved. THA-US-0325



Chinese American Hematologist and Oncologist Network (CAHON) 555 East Wells Street, Suite 1100 • Milwaukee, WI 53202 USA Phone: 1 414-918-9890 • Fax: 1 414-276-3349